SEARCH

SEARCH BY CITATION

References

  • 1
    Pneumocystis pneumonia – Los Angeles. MMWR. Morbidity and mortality weekly report 1981. 30: 250–252.
  • 2
    Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C. et al., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983. 220: 868871.
  • 3
    UNAIDS, Global Report: UNAIDS Report on the Global AIDS Epidemic: 2010. UN Joint Programme on HIV/AIDS 2010.
  • 4
    Levy, J. A., The Retroviridae, Plenum Press, New York 1992.
  • 5
    Levy, J. A., HIV and The Pathogenesis of AIDS, (3rd Edn), ASM Press, Washington, D.C. 2007.
  • 6
    Luciw, P. A., Potter, S. J., Steimer, K., Dina, D. and Levy, J. A., Molecular cloning of AIDS-associated retrovirus. Nature 1984. 312: 760763.
  • 7
    Hemelaar, J., Gouws, E., Ghys, P. D. and Osmanov, S., Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011. 25: 679689.
  • 8
    Baeten, J. M., Chohan, B., Lavreys, L., Chohan, V., McClelland, R. S., Certain, L., Mandaliya, K., Jaoko, W. and Overbaugh, J., HIV-1 subtype D infection is associated with faster disease progression than subtype A is spite of smaller plasma HIV-1 loads. J. Infect. Dis. 2007. 195: 11771180.
  • 9
    Miura, T., Brockman, M. A., Brumme, C. J., Brumme, Z. L., Carlson, J. M., Pereyra, F., Trocha, A. et al., Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 2008. 82: 84228430.
  • 10
    Bailey, J. R., O'Connell, K., Yang, H. C., Han, Y., Xu, J., Jilek, B., Williams, T. M. et al., Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J. Virol. 2008. 82: 73957410.
  • 11
    Gottlieb, M. S., Schroff, R., Schanker, H. M., Weisman, J. D., Fan, P. T., Wolf, R. A. and Saxon, A., Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 1981. 305: 14251431.
  • 12
    Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T., Gluckman, J. C. and Montagnier, L., T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984. 312: 767768.
  • 13
    Cheng-Mayer, C., Seto, D., Tateno, M. and Levy, J. A., Biologic features of HIV-1 that correlate with virulence in the host. Science 1988. 240: 8082.
  • 14
    Tersmette, M., de Goede, R. E., Al, B. J., Winkel, I. N., Gruters, R. A., Cuypers, H. T., Huisman, H. G. and Miedema, F., Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 1988. 62: 20262032.
  • 15
    Berger, E. A., Murphy, P. M. and Farber, J. M., Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999. 17: 657700.
  • 16
    Takeuchi, H. and Matano, T., Host factors involved in resistance to retroviral infection. Microbiol. Immunol. 2008. 52: 318325.
  • 17
    Neil, S. and Bieniasz, P., Human immunodeficiency virus, restriction factors, and interferon. J. Interferon Cytokine Res. 2009. 29: 569580.
  • 18
    Lim, E. S. and Emerman, M., HIV: Going for the watchman. Nature 2011. 474: 587588.
  • 19
    Vazquez, N., Schmeisser, H., Dolan, M. A., Bekisz, J., Zoon, K. C. and Wahl, S. M., Structural variants of IFNalpha preferentially promote antiviral functions. Blood 2011. 118: 25672577.
  • 20
    Tugizov, S. M., Herrera, R., Veluppillai, P., Greenspan, D., Soros, V., Greene, W. C., Levy, J. A. and Palefsky, J. M., HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology 2011. 409: 211222.
  • 21
    Dinkins, C., Arko-Mensah, J. and Deretic, V., Autophagy and HIV. Semin. Cell Dev. Biol. 2010. 21: 712718.
  • 22
    Peruzzi, F., The multiple functions of HIV-1 Tat: proliferation versus apoptosis. Front. Biosci. 2006. 11: 708717.
  • 23
    Kwon, H. S., Brent, M. M., Getachew, R., Jayakumar, P., Chen, L. F., Schnolzer, M., McBurney, M. W. et al., Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 2008. 3: 158167.
  • 24
    Margolis, D. M., Mechanisms of HIV latency: an emerging picture of complexity. Curr. HIV/AIDS Rep. 2010. 7: 3743.
  • 25
    Levy, J. A., The transmission of AIDS: the case of the infected cell. J. Am. Med. Assoc. 1988. 259: 30373038.
  • 26
    Cohen, M. S., Shaw, G. M., McMichael, A. J. and Haynes, B. F., Acute HIV-1 Infection. N. Engl. J. Med. 2011. 364: 19431954.
  • 27
    Salazar-Gonzalez, J. F., Salazar, M. G., Keele, B. F., Learn, G. H., Giorgi, E. E., Li, H., Decker, J. M. et al., Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009. 206: 12731289.
  • 28
    Douek, D., HIV disease progression: immune activation, microbes, and a leaky gut. Top. HIV Med. 2007. 15: 114117.
  • 29
    Norris, P. J., Pappalardo, B. L., Custer, B., Spotts, G., Hecht, F. M. and Busch, M. P., Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res. Hum. Retroviruses 2006. 22: 757762.
  • 30
    Munoz, A., Wang, M. C., Bass, S., Taylor, J. M., Kingsley, L. A., Chmiel, J. S. and Polk, B. F., Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. Am. J. Epidemiol. 1989. 130: 530539.
  • 31
    Deeks, S. G. and Walker, B. D., Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007. 27: 406416.
  • 32
    Young, J. M., Turpin, J. A., Musib, R. and Sharma, O. K., Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals. AIDS Res. Hum. Retroviruses 2011. 27: 737743.
  • 33
    Giorgi, J. V., Liu, Z., Hultin, L. E., Cumberland, W. G., Hennessey, K. and Detels, R., Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 1993. 6: 904912.
  • 34
    Effros, R. B., Allsopp, R., Chiu, C. P., Hausner, M. A., Hirji, K., Wang, L., Harley, C. B. et al., Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996. 10: F17F22.
  • 35
    Cummins, N. W. and Badley, A. D., Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis. 2010. 1: e99.
  • 36
    Favre, D., Mold, J., Hunt, P. W., Kanwar, B., Loke, P., Seu, L., Barbour, J. D. et al., Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2010. 2: 32ra36.
  • 37
    Herbeuval, J. P. and Shearer, G. M., HIV-1 immunopathogenesis: how good interferon turns bad. Clin. Immunol. 2007. 123: 121128.
  • 38
    Manches, O. and Bhardwaj, N., Resolution of immune activation defines nonpathogenic SIV infection. J. Clin. Invest. 2009. 119: 35123515.
  • 39
    Fazekas de St Groth, B. and Landay, A. L., Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS 2008. 22: 671683.
  • 40
    Kinter, A. L., Horak, R., Sion, M., Riggin, L., McNally, J., Lin, Y. and Jackson, R., CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res. Hum. Retroviruses 2007. 23: 438450.
  • 41
    Billerbeck, E. and Thimme, R., CD8+ regulatory T cells in persistent human viral infections. Hum. Immunol. 2008. 69: 771775.
  • 42
    Elahi, S., Dinges, W. L., Lejarcegui, N., Laing, K. J., Collier, A. C., Koelle, D. M., McElrath, M. J. and Horton, H., Protective HIV-specific CD8(+) T cells evade T(reg) cell suppression. Nat. Med. 2011. 17: 989995.
  • 43
    Walker, C. M., Moody, D. J., Stites, D. P. and Levy, J. A., CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986. 234: 15631566.
  • 44
    Levy, J. A., The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol. 2003. 24: 628632.
  • 45
    Levy, J. A., Scott, I. and Mackewicz, C., Protection from HIV/AIDS: the importance of innate immunity. Clin. Immunol. 2003. 108: 167174.
  • 46
    Barker, E., Mackewicz, C. E., Reyes-Teran, G., Sato, A., Stranford, S. A., Fujimura, S. H., Christopherson, C. et al., Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998. 92: 31053114.
  • 47
    Killian, M. S., Johnson, C., Teque, F., Fujimura, S. and Levy, J. A., Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J. Virol. 2011. 85: 16961705.
  • 48
    Wong, J. K., Strain, M. C., Porrata, R., Reay, E., Sankaran-Walters, S., Ignacio, C. C., Russell, T. et al., In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 2010. 6: e1000748.
  • 49
    Klatt, N. R., Shudo, E., Ortiz, A. M., Engram, J. C., Paiardini, M., Lawson, B., Miller, M. D., et al., CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 2010. 6: e1000747.
  • 50
    Stranford, S. A., Skurnick, J., Louria, D., Osmond, D., Chang, S. Y., Sninsky, J., Ferrari, G. et al., Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci. USA 1999. 96: 10301035.
  • 51
    Levy, J. A., Hsueh, F., Blackbourn, D. J., Wara, D. and Weintrub, P. S., CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. J. Infect. Dis. 1998. 177: 470472.
  • 52
    Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. and Lusso, P., Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995. 270: 18111815.
  • 53
    Walker, B. D., Chakrabarti, S., Moss, B., Paradis, T. J., Flynn, T., Durno, A. G., Blumberg, R. S. et al., HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987. 328: 345348.
  • 54
    Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. and Oldstone, M. B., Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 1994. 68: 61036110.
  • 55
    Pereyra, F., Jia, X., McLaren, P. J., Telenti, A., de Bakker, P. I., Walker, B. D., Ripke, S. et al., The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010. 330: 15511557.
  • 56
    Kaslow, R. A., Carrington, M., Apple, R., Park, L., Muoz, A., Saah, A. J., Goedert, J. J. et al., Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 1996. 2: 405411.
  • 57
    Miura, T., Brockman, M. A., Schneidewind, A., Lobritz, M., Pereyra, F., Rathod, A., Block, B. L. et al., HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J. Virol. 2009. 83: 27432755.
  • 58
    Moore, C. B., John, M., James, I. R., Christiansen, F. T., Witt, C. S. and Mallal, S. A., Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002. 296: 14391443.
  • 59
    Berger, C. T., Frahm, N., Price, D. A., Mothe, B., Ghebremichael, M., Hartman, K. L., Henry, L. M. et al., High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted gag-derived epitopes associated with relative HIV control. J. Virol. 2011. 85: 93349345.
  • 60
    Bashirova, A. A., Thomas, R. and Carrington, M., HLA/KIR restraint of HIV: surviving the fittest. Annu. Rev. Immunol. 2011. 29: 295317.
  • 61
    Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H., Nelson, J. A. et al., Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 1997. 3: 205211.
  • 62
    Kawashima, Y., Pfafferott, K., Frater, J., Matthews, P., Payne, R., Addo, M., Gatanaga, H. et al., Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009. 458: 641645.
  • 63
    Addo, M. M., Yu, X. G., Rathod, A., Cohen, D., Eldridge, R. L., Strick, D., Johnston, M. N. et al., Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003. 77: 20812092.
  • 64
    Appay, V., Nixon, D. F., Donahoe, S. M., Gillespie, G. M., Dong, T., King, A., Ogg, G. S. et al., HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 2000. 192: 6375.
  • 65
    Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W. et al., PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006. 443: 350354.
  • 66
    Young, J. M., Turpin, J. A., Musib, R. and Sharma, O. K., Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals. AIDS Res. Hum. Retroviruses 2011. 27: 737743.
  • 67
    Lieberman, J., Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS 2004. 18: 14891493.
  • 68
    Richman, D. D., Wrin, T., Little, S. J. and Petropoulos, C. J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2003. 100: 41444149.
  • 69
    Cagigi, A., Nilsson, A., De Milito, A. and Chiodi, F., B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 2008. 26: 30163025.
  • 70
    Epeldegui, M., Vendrame, E. and Martinez-Maza, O., HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol. Res. 2010. 48: 7283.
  • 71
    Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J. P., Wang, S. K. et al., Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011. 477: 466470.
  • 72
    Pereyra, F., Palmer, S., Miura, T., Block, B. L., Wiegand, A., Rothchild, A. C., Baker, B. et al., Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 2009. 200: 984990.
  • 73
    Lambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H. X., Parks, R. J., Hicks, C. B. et al., Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009. 23: 897906.
  • 74
    Forthal, D. N., Landucci, G., Cole, K. S., Marthas, M., Becerra, J. C. and Van Rompay, K., Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 2006. 80: 92179225.
  • 75
    Chung, A. W., Isitman, G., Navis, M., Kramski, M., Center, R. J., Kent, S. J. and Stratov, I., Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc. Natl. Acad. Sci. USA 2011. 108: 75057510.
  • 76
    Homsy, J., Meyer, M. and Levy, J. A., Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 1990. 64: 14371440.
  • 77
    Altfeld, M., Fadda, L., Frleta, D. and Bhardwaj, N., DCs and NK cells: critical effectors in the immune response to HIV-1. Nature Rev. Immunol. 2011. 11: 176186.
  • 78
    Castelli, J., Thomas, E. K., Gilliet, M., Liu, Y. J. and Levy, J. A., Mature dendritic cells can enhance CD8+ cell noncytotoxic anti-HIV responses: the role of IL-15. Blood 2004. 103: 26992704.
  • 79
    Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S. and Liu, Y. J., The nature of the principal type 1 interferon-producing cells in human blood. Science 1999. 284: 18351837.
  • 80
    Soumelis, V., Scott, I., Liu, Y. J. and Levy, J., Natural type 1 interferon producing cells in HIV infection. Hum. Immunol. 2002. 63: 12061212.
  • 81
    Killian, M. S., Fujimura, S. H., Hecht, F. M. and Levy, J. A., Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS 2006. 20: 12471252.
  • 82
    Schmidt, B., Ashlock, B. M., Foster, H., Fujimura, S. H. and Levy, J. A., HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 2005. 343: 256266.
  • 83
    Alter, G., Heckerman, D., Schneidewind, A., Fadda, L., Kadie, C. M., Carlson, J. M., Oniangue-Ndza, C. et al., HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011. 476: 96100.
  • 84
    Poropatich, K. and Sullivan, D. J., Jr., Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J. Gen. Virol. 2011. 92: 247268.
  • 85
    Fellay, J., Shianna, K. V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K. et al., A whole-genome association study of major determinants for host control of HIV-1. Science 2007. 317: 944947.
  • 86
    Yang, O. O., Kalams, S. A., Trocha, A., Cao, H., Luster, A., Johnson, R. P. and Walker, B. D., Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 1997. 71: 31203128.
  • 87
    Kamya, P., Boulet, S., Tsoukas, C. M., Routy, J. P., Thomas, R., Cote, P., Boulassel, M. R. et al., Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J. Virol. 2011. 85: 59495960.
  • 88
    Sobieszczyk, M. E., Lingappa, J. R. and McElrath, M. J., Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr. Opin. HIV AIDS 2011. 6: 427434.
  • 89
    Volberding, P. A. and Deeks, S. G., Antiretroviral therapy and management of HIV infection. Lancet 2010. 376: 4962.
  • 90
    Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G. et al., Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011. 365: 493505.
  • 91
    Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P. et al., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010. 363: 25872599.
  • 92
    Anglemyer, A., Rutherford, G. W., Egger, M. and Siegfried, N., Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst. Rev. 2011. 8: CD009153.
  • 93
    Blanco, J. R., Caro, A. M., Perez-Cachafeiro, S., Gutierrez, F., Iribarren, J. A., Gonzalez-Garcia, J., Ferrando-Martinez, S. et al., HIV infection and aging. AIDS Rev. 2010. 12: 218230.
  • 94
    Hontelez, J. A., Lurie, M. N., Newell, M. L., Bakker, R., Tanser, F., Barnighausen, T., Baltussen, R. and de Vlas, S. J., Ageing with HIV in South Africa. AIDS 2011. 25: 16651667.
  • 95
    Allers, K., Hutter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E. and Schneider, T., Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011. 117: 27912799.
  • 96
    Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G. M. et al., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 2010. 28: 839847.
  • 97
    Choudhary, S. K. and Margolis, D. M., Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 2011. 51: 397418.
  • 98
    Sahu, G. K. and Cloyd, M. W., Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virology J. 2011. 8: 400.
  • 99
    Munier, C. M., Andersen, C. R. and Kelleher, A. D., HIV vaccines: progress to date. Drugs 2011. 71: 387414.
  • 100
    Li, F., Finnefrock, A. C., Dubey, S. A., Korber, B. T., Szinger, J., Cole, S., McElrath, M. J. et al., Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the step study. PloS one 2011. 6: e20479.
  • 101
    Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N. et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009. 361: 22092220.
  • 102
    Korber, B. and Gnanakaran, S., AIDS/HIV. Converging on an HIV vaccine. Science 2011. 333: 15891590.
  • 103
    Yamamoto, J. K., Pu, R., Sato, E. and Hohdatsu, T., Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine. AIDS 2007. 21: 547563.
  • 104
    Craigo, J. K. and Montelaro, R. C., EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr. HIV Res. 2010. 8: 8186.